It's getting mighty crowded in biotech's hippest neighborhood

Biotech's extended hot streak has put loads of money in the pockets of drugmakers, and nowhere is that clearer than in Cambridge, MA, where the boom has created demand for lab space that is outpacing supply. As CNBC reports, Cambridge's Kendall Square neighborhood, home to some industry titans, is facing historically low vacancy rates despite rising rents. More

Suggested Articles

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.

Lilly commited $820 million in development milestones for the chance to work with Sitryx on drugs that manipulate intracellular metabolic pathways.